Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx (Nasdaq: CDNA) agreed to acquire Naveris, a commercial-stage precision oncology diagnostics company, for $160 million up-front plus up to $100 million in revenue-based earnouts. The Naveris TTMV® liquid biopsy is Medicare-reimbursed and reported $34 million revenue in 2025.
CareDx expects Naveris revenue to grow 30–40% annually over three years, reported Q1 2026 unaudited revenue of ~$12 million, 65% gross margin, and a Q1 net operating loss of $0.2 million. Transaction expected to close in Q3 2026 and is forecasted to be neutral to CareDx's FY2026 adjusted EBITDA guidance.
CareDx (Nasdaq: CDNA) reported Q1 2026 revenue of $118M, up 39% year-over-year, driven by Testing Services of $91M (+48%) and volumes ~54,900 (+17%). GAAP net income was $3M; adjusted EBITDA was $19M. Company raised 2026 revenue guidance to $447M–$465M and adjusted EBITDA to $43M–$57M, announced a $170M lab-products divestiture agreement and a $100M share repurchase authorization.
CareDx (Nasdaq: CDNA) will present 50 abstracts, 16 oral presentations and two symposia at ISHLT 2026 (April 22–25) featuring data from 95 transplant centers. Key findings from SHORE (≈2,700 heart transplant patients) and ALAMO support non-invasive HeartCare and AlloSure Lung for early injury detection, longitudinal risk assessment, and surveillance cost comparisons.
CareDx also described MERIT, a randomized trial testing management guided by dual-positive molecular results in heart transplant recipients.
CareDx (Nasdaq: CDNA) introduced AlloSeq Nano, a nanopore long‑read HLA and ABO genotyping assay delivering high‑resolution results in under three hours and about 45 minutes hands‑on for eleven HLA loci plus ABO.
The company is showcasing AlloSeq Nano at EFI 2026 on April 23 and announced a definitive agreement to divest its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026.
CareDx (Nasdaq: CDNA) agreed to sell its Lab Products business to EuroBio Scientific for $170 million, aiming to sharpen focus on Precision Medicine Testing Services and Patient and Digital Solutions.
Key terms include a perpetual North America distribution right for post-transplant IVD tests including AlloSeq cfDNA, expected close by end of Q3 2026 pending Swedish regulatory review, and at least six months of transition services. Preliminary Q1 2026 results: $118M revenue (+39% YoY), Testing Services revenue $91M (+48% YoY), testing volume ~54,900 (+17% YoY), Patient and Digital $16M (+33%), Lab Products $10M (-4%), and cash ~$198M as of March 31, 2026.
CareDx (Nasdaq: CDNA) will report first quarter 2026 financial results after market close on April 28, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET that day.
A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website; telephone participants must register to receive a dial-in number and PIN.
CareDx (Nasdaq: CDNA) launched VANTx, an AI‑powered, cloud‑native clinical data and analytics platform announced March 5, 2026. VANTx ingests real‑time, de‑identified molecular and clinical data, runs on Databricks with the Llama 3 foundational model, and supports cohort analysis, research, and real‑world evidence generation.
Available now via medical affairs consultation, CareDx plans self‑service, permissioned clinician access later in 2026.
CareDx (Nasdaq: CDNA) awarded inducement restricted stock unit grants to 35 new employees totaling 82,137 RSUs on February 24, 2026, under its 2016 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years: 25% on the first anniversary of each employee's vesting commencement date and then 1/16th quarterly thereafter, subject to continued service.
CareDx (Nasdaq: CDNA) announced that Keith Kennedy, currently Chief Operating Officer, will also assume the role of Chief Financial Officer effective February 26, 2026.
Kennedy brings over 20 years of healthcare leadership, seven years of public-company CFO experience, prior CFO roles including PharmaLogic (Apr 2022–Sep 2024), and credentialing as a CFA and CPA. Nathan Smith will step down as CFO, as announced on the company’s quarterly earnings call.
Summary not available.